Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tucatinib - Array BioPharma/Seattle Genetics

Drug Profile

Tucatinib - Array BioPharma/Seattle Genetics

Alternative Names: ARRY-380; Irbinitinib; ONT-380

Latest Information Update: 23 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; Cascadian Therapeutics; Dana-Farber Cancer Institute; Seattle Genetics
  • Class 2 ring heterocyclic compounds; Antineoplastics; Diamines; Furans; Pyridines; Quinazolinones; Small molecules; Triazoles
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain metastases; Colorectal cancer; Breast cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Colorectal cancer
  • No development reported Solid tumours

Most Recent Events

  • 21 Oct 2019 Seattle Genetics plans to file an NDA with the US FDA for Breast cancer in the first quarter of 2020
  • 21 Oct 2019 Positive top-line efficacy data and adverse events from the phase II HER2CLIMB trial in Breast cancer released by Seattle Genetics
  • 30 Sep 2019 Adverse events and Therapeutic trials data from a phase II trial in Colorectal cancer presented at the European Society for Medical Oncology (ESMO-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top